TRX BioSurgery GPO agreement with Premier, Inc.

RNS Number : 8203M

Tissue Regenix Group PLC

02 May 2018

 

TRX BioSurgery extends GPO agreement with Premier, Inc.

Under a  3 year Tissue, Implantable Products contract DermaPure maintains access to c. 3,900 U.S. hospitals and         > 150,000 provider organisations

Leeds, 2 May 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, today announced subsidiary TRX BioSurgery has been awarded a group purchasing contract for DermaPure under a Tissue, Implantable Products contract with Premier Inc., a leading healthcare improvement company, effective for three years commencing 1 July, 2018.  

Since the initial approval under Premier's 'Breakthrough Technology Agreement' in December 2016, DermaPure has gained clinical support throughout Premier's member institutions. Under this new agreement Tissue Regenix salesforce maintains commercial access to Premier's alliance of approximately 3,900 U.S. hospitals and more than 150,000 care providers.

DermaPure has demonstrated clinical and health economic advantages for inpatient applications. The product  has been increasingly deployed in a number of clinical areas including acute and chronic wound care, orthopaedic trauma, dental, and following the exclusive distribution agreement with ARMS medical, urogynaecology and urology. 

Joel Pickering, President TRX BioSurgery, commented: "We are thrilled to extend our relationship with Premier, Inc. and to continue to make DermaPure accessible to its member institutions.  The award of this new agreement highlights the need for novel products such as DermaPure in a growing number of clinical areas.  We strive to achieve superior clinical outcomes and contribute to improved health economics for both patients and health care providers alike. Now with the capacity to manufacture product inhouse at our CellRight facility and with growing advocacy of DermaPure throughout the clinical community, the addition of this agreement will enable us to continue to meet their clinical needs now and in the future."

For more Information:

Tissue Regenix Group plc Caitlin Pearson, Head of Communications	Tel: [phone]
Jefferies International Ltd Simon Hardy / Christopher Binks	Tel:  [phone]
FTI Consulting  Brett Pollard / Mo Noonan/ Mary Whittow	Tel: [phone]

 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

About Premier Inc.

Premier Inc. (NASDAQ: PINC) is a healthcare improvement company uniting an alliance of approximately 3,900 U.S. hospitals and more than 150,000 other provider organizations. Our mission is simple: To improve the health of communities.

As an industry leader, Premier has created one of the most comprehensive databases of actionable data, clinical best practices and efficiency improvement strategies.

Our award-winning and revolutionary technologies enable our members to collaborate more easily and efficiently. Our goal is to improve our members' quality outcomes, while safely reducing costs. By engaging members and revealing new opportunities, we empower the alliance to improve the performance of healthcare organizations.

Named one of the World's Most Ethical Companies 10 years in a row, we are well-equipped to transform the future of healthcare.

Please visit Premier's news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier's blog for more information about the company.

 

END

 

 

CNTMMGGKMMKGRZZ